ARK Genomic Revolution ETF vs Vanguard Total International Stock Index Fund ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.91, while Vanguard Total International Stock Index Fund ETF trades at $84.43. Which is the better fit depends on your goals.
| ARKG | VXUS | |
|---|---|---|
Sector | Sector/Thematic | Sector/Thematic |
52-Week High | $43.57 | $87.06 |
52-Week Low | $23.09 | $68.24 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
VXUS trades at $85.34, up 0.52% on the day, with a neutral technical signal and bullish moving averages. The ETF offers broad international equity exposure across 8,738 stocks, providing diversification benefits. Recent news highlights its role in portfolio construction amid high U.S. valuations, with Vanguard surpassing iShares as the largest ETF provider in June 2026.
The outlook for VXUS is supported by its low-cost structure and global diversification, appealing for long-term investors seeking non-U.S. exposure. Risks include currency fluctuations and emerging market volatility. Analyst sentiment is neutral, with the ETF positioned as a core holding for balanced portfolios.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →